Ryzodeg Articles
Blow for Novo Nordisk, as FDA further delays Tresiba and Ryzodeg
11 February 2013
Japanese approvals for Novo's Ryzodeg, UCB/Otsuka's Neupro and B-MS/Pfizer's Eliquis
27 December 2012
FDA briefing papers for Novo Nordisk's insulin degludec note need to review cardiac risks
6 November 2012
FDA further delays Novo Nordisk's ultra long-acting insulin products Tresiba and Ryzodeg
19 July 2012
Novo Nordisk starts year with 15% net profits hike
30 April 2012
Showing 1-10 of 10 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
